NSCLC
Conditions
Brief summary
This is a prospective, open, single-center, single-arm phase II clinical study in non-small cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK fusion variants identified in the central laboratory. To evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
Interventions
DRUGToripalimab
This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The subjects will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures; * Male and female, ≥18 years old; * Primary non-squamous NSCLC confirmed histologically by the central laboratory; * The subject was clinically confirmed as stage IA2-IB by imaging with tumor lesion size \> 2 cm; * As confirmed by the central laboratory, the tumor contains no common EGFR mutations and ALK fusion variants; * The primary NSCLC must be completely resected by surgery, and all lesions must be removed at the end of the surgery.All surgical margins must be negative. Lobectomy can be done with open surgery or thoracoscopic (VATS); * Central laboratory pathology confirmed solid and/or micropapillary component ≥10%, and/or STAS, and/or pleural invasion, and/or poorly differentiated, and/or complex glands ≥ 10%; PD-L1 TPS ≥ 1% in tumor tissue; * WHO physical status score is 0\ 1; * Paraffin-embedded sections (10-15 sheets), or wax blocks or fresh frozen tissue for surgical resection of the lesion should be provided; * Adequate bone marrow reserve or organ function (demonstrated by any of the following laboratory values: absolute neutrophil count ≥1.5×10⁹/L; Platelet count ≥100×10⁹/L; Hemoglobin ≥90 g/L; Alanine aminotransferase ≤ 2.5 ULN; Aspartate aminotransferase ≤2.5 times ULN; Total bilirubin ≤ 1.5 ULN; Serum creatinine ≤1.5 ULN with creatinine clearance ≥60 mL/min \[as measured or calculated by Cockcroft and Gault formulas\]); * At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug * Subjects voluntarily join this study, with good compliance and cooperation in safety and survival follow-up.
Exclusion criteria
* Exposure to other antitumor therapies before enrollment; * Patients who only received segmental resection and wedge resection; * Patients with any history of active autoimmune disease or autoimmune disease; * Complicated diseases that require the use of immunosuppressive drugs; concurrent diseases that require the use of immunosuppressive agents for systemic or locally absorbable corticosteroids; * Combined with severe heart disease, or combined with New York Heart Association (NYHA) grade 3 or 4 cardiac insufficiency; * Any evidence of prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or active interstitial lung disease; * Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, any condition that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV); * Have received preventive or attenuated vaccines within 4 weeks before the first administration; * Patients are unsuitable for participation in this research after comprehensive assessment by the researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year DFS rate | From date of randomisation up to approximately 5 years | DFS is defined as time from randomization to disease recurrence (determined by CT or MRI scan and/or pathologic disease on biopsy) or death (from any cause) by investigator assessment. 3-year DFS rate is Disease-Free Survival at 3 Years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DFS | From date of randomisation up to approximately 10 years | DFS is defined as time from randomization to disease recurrence (determined by CT or MRI scan and/or pathologic disease on biopsy) or death (from any cause) by investigator assessment. |
| 3-year OS rate | From date of randomization up to approximately 5 years | Defined as the percentage of patients alive at 3 years, respectively, estimated from a Kaplan Meier plot of OS at the time of the primary analysis |
| 5-year OS rate | From date of randomization up to approximately 5 years | Defined as the percentage of patients alive at 5 years, respectively, estimated from a Kaplan Meier plot of OS at the time of the primary analysis |
| OS | From date of randomization up to approximately 10 years | OS is defined as the time from the date of randomisation until death due to any cause. |
| Safety and tolerability in overall population | From date of randomisation up to approximately 10 years | AEs graded by CTCAE version 5.0 |
Countries
China
Contacts
Primary ContactDongsheng Yue
Outcome results
None listed